Novo Nordisk to present early-stage trial data for new diabetes drug at investor meeting

Novo Nordisk, maker of obesity drug Wegovy, on Thursday said it would present early-stage trial data for its highly anticipated pipeline drug, Amycretin, for treatment of Type 2 diabetes.

The company said in a statement that it will present the data as it hosts investors and analysts at its headquarters near Copenhagen for the first strategy update since Wegovy exploded in popularity. Its market capitalisation stood at about $560 billion going into the meeting compared with around $235 billion two years ago when it last held an investor day.